Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
Por:
Galsky, MD, Van Der Heijden, MS, Catto, JWF, Al-Ahmadie, H, Meeks, JJ, Nishiyama, H, Drakaki, A, Vu, TQ, Antonuzzo, L, Atduev, V, Kann, AG, Kim, TH, Pous, AF, Chang, CH, De Wit, R, Wojtukiewicz, MZ, Xin, WJ, Donegan, SE, Hois, S and Powles, T
Publicada:
10 feb 2025
Resumen:
Filiaciones:
Icahn Sch Med Mt Sinai, New York, NY USA
Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
Univ Sheffield, Div Clin Med, Sheffield, England
Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA
Northwestern Univ, Feinberg Sch Med, Dept Urol Biochem & Mol Genet, Chicago, IL USA
Univ Tsukuba, Fac Med, Dept Urol, Tsukuba, Ibaraki, Japan
UCLA, Div Hematol Oncol, David Geffen Sch Med, Los Angeles, CA USA
Vietnam Natl Canc Hosp, Dept Internal Med 3, Hanoi, Vietnam
Univ Florence, Dept Expt & Clin Med, Florence, Italy
Careggi Univ Hosp, Med Oncol Unit, Florence, Italy
Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia
Hosp Alemao Oswaldo Cruz, Clin Oncol, Sao Paulo, Brazil
Kyungpook Natl Univ, Dept Urol, Sch Med, Daegu, South Korea
Hosp Univ Germans Trias i Pujol, Inst Catala Oncol, Med Oncol Dept, Badalona Appl Res Grp Oncol BARGO, Barcelona, Spain
China Med Univ & Hosp, Dept Urol, Taichung, Taiwan
China Med Univ & Hosp, Sch Med, Taichung, Taiwan
Erasmus MC, Dept Med Oncol, Div Lead Genito Urinary Clin Res, Rotterdam, Netherlands
Maria Sklodowska Curie Bialystok Oncol Ctr, Bialystok, Poland
AstraZeneca, Gothenburg, Sweden
AstraZeneca, Gaithersburg, MD USA
Queen Mary Univ London, Barts Canc Inst, London, England
|